Muscarinic receptor antagonists in the treatment of overactive bladder.
about
Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.Pathophysiology, Clinical Importance, and Management of Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral Spinal Cord InjuryDependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channelsLack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.Single compartment drug delivery.Efficacy and safety of ginger-salt-indirect moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicentre randomised controlled trial.Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonistsPharmacokinetics and safety of solifenacin succinate in healthy young men.Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.Current pharmacotherapeutic strategies for overactive bladder.Evaluation and treatment of the overactive bladder.Urinary metabolite profiling combined with computational analysis predicts interstitial cystitis-associated candidate biomarkersIncreased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapyApproach to urinary incontinence in women. Diagnosis and management by family physicians.Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Purinoceptors as therapeutic targets for lower urinary tract dysfunction.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderInterstitial cystitis and frequency-urgency syndrome (OAB syndrome).The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.Botulinum toxin in neurogenic detrusor overactivity.A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary BladderSpinal reflex control of micturition after spinal cord injury.Developments in pharmacological therapy for the overactive bladder.Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.A review of solifenacin in the treatment of urinary incontinence.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Development of oxybutynin chloride topical gel for overactive bladderPatient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.Muscarinic acetylcholine receptors as effector sites for present and future therapeutic applications: focus on non-neural cholinergic systems.Urinary incontinence: pharmacotherapy options.Solifenacin for overactive bladder: a systematic review and meta-analysis.The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
P2860
Q24812265-B456F5D1-87B1-49F9-83B1-025371238A57Q26741369-1B14C2FC-C177-49D4-9CD6-3CC9E0B8CAE0Q28346720-4CCD3C39-6525-4E4C-967B-B66E1B5074FFQ32039057-0F879682-0953-4579-AE07-AE8E425DF870Q34104589-BBA13BED-1FF4-4E68-8676-D0D13EDBBED7Q34263907-0EAE7601-7757-43CF-9E0A-A9BA78A92E26Q34397227-D9213467-0E00-47D8-9E25-6DCF46E285EEQ34543969-D23A4D72-58B0-4E0D-8C1D-98CA15C16050Q34548809-1D8202B2-F5B2-4A81-BF16-D251B742602DQ34550245-FC41DE30-9599-4389-A968-0761D65214FAQ34569114-828C1EDC-3F12-4F81-9BB2-8055C8D7A4BDQ34706864-ACF370B5-C23C-4A23-A125-9C4FECFC6FE6Q34778719-87C917BC-86A0-4202-A662-FD7F2E6285BEQ34855915-4AF45AA7-AC94-4217-B202-3AD81F92BA9DQ35009629-4B8AD1E5-F561-4C70-BD1B-AE4996B0BEEDQ35146953-CEF85775-A564-44E2-880D-390AA4DF24C5Q35419834-EB366299-BAEF-4EB2-A84F-78F18288B37DQ35545723-7B56FFCB-2ED8-4E1B-81A2-FD0A0ACA0FE6Q35546189-D4CCE924-78B4-41F1-B608-3C5D029545C0Q35594530-ADEC2769-C3AB-4F7C-BC13-EF1495518477Q35798421-1ADE20AE-BE07-45B6-93B2-605E81C6CE6BQ35908570-70AB0EC1-88E0-4062-886E-958B3F455823Q36192782-E29B0D84-C0F6-4401-B2EE-82FCC153FBFBQ36313192-C504E413-AAD6-429F-8653-A237D06E5182Q36432305-07627B45-B019-4727-A3FE-3CF4DF32CA21Q36487107-7D5641EC-36DC-47D5-BFA8-6A37A8C62FBAQ36566857-C31693E1-590D-4EC9-85C9-DC5A74072A61Q36804908-BBB7CDC6-7DA2-4F61-85C8-461067E3E20EQ36822864-B5C06302-AB0F-47BD-A638-62847C4910DBQ37187453-C8F287BE-63D4-4029-9DFA-D93D339ACA63Q37283717-83F38B92-786C-40BF-A567-C18773D648D5Q37405499-A0B4E049-2ED0-4A69-96B5-175CC79A7732Q37642772-1479B8D8-BE02-47E5-82F7-4A16298E3D75Q37682186-7135B573-4785-450E-9B5E-F5523D540170Q37689776-83553A68-0BA1-446D-96D5-FF39F293E9BDQ37884579-DC3E9DD5-A987-410D-879B-C5D777E97C72Q37981898-2B24A498-830C-4099-9344-59A250B097B7Q38200003-C1D52758-8CE9-45DB-8944-DFC5AA009175Q38217760-C54DE4DB-AFCF-4BAD-9CFB-5B8E8A9D192EQ38338125-E6494017-A1F3-4353-8BCF-EC757F839DBE
P2860
Muscarinic receptor antagonists in the treatment of overactive bladder.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Muscarinic receptor antagonists in the treatment of overactive bladder.
@ast
Muscarinic receptor antagonists in the treatment of overactive bladder.
@en
type
label
Muscarinic receptor antagonists in the treatment of overactive bladder.
@ast
Muscarinic receptor antagonists in the treatment of overactive bladder.
@en
prefLabel
Muscarinic receptor antagonists in the treatment of overactive bladder.
@ast
Muscarinic receptor antagonists in the treatment of overactive bladder.
@en
P1433
P1476
Muscarinic receptor antagonists in the treatment of overactive bladder.
@en
P2093
Chapple CR
P304
33-46; discussion 50
P356
10.1016/S0090-4295(99)00492-6
P407
P433
P577
2000-05-01T00:00:00Z